Molecular Insight Pharm. , Nasdaq: MIPI
Developing radiopharmaceuticals to treat cancer and targeted diagnostic tests.
Industry: Health Care
First Day Return: +0.6%
Industry: Health Care
MIPI
Developing radiopharmaceuticals to treat cancer and targeted diagnostic tests.
| IPO Data | |
|---|---|
| IPO File Date | 11/08/2005 |
| Offer Price | $14.00 |
| Price Range $14.00 - $16.00 | |
| Offer Shares (mm) | 5.0 |
| Deal Size ($mm) | $70 |
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
| IPO Data | |
|---|---|
| IPO Date | 02/01/2007 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $70 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Cambridge, MA, United States |
| Founded | 1997 |
| Employees at IPO | 37 |
| Website www.molecularinsight.com | |
IPO News for Molecular Insight Pharm.
Molecular Insight Pharm. (MIPI) Performance
